We are live on ! Find out more
TXMD icon

TherapeuticsMD
TXMD

46 hedge funds and large institutions have $3.54M invested in TherapeuticsMD in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

10% more funds holding

Funds holding: 42 → 46 (+4)

0.41% more ownership

Funds ownership: 28.13% → 28.55% (+0.41%)

6% less capital invested

Capital invested by funds: $3.78M → $3.54M (-$234K)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
11
Closed
3
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$60K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$38.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$23.1K
3
TSS
Two Sigma Securities
New York
+$1.72K
4
Barclays
Barclays
United Kingdom
+$49
5
Osaic Holdings
Osaic Holdings
Arizona
+$40

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.64K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$2.44K
3
Morgan Stanley
Morgan Stanley
New York
-$715
4
Raymond James Financial
Raymond James Financial
Florida
-$617
5
Simplex Trading
Simplex Trading
Illinois
-$480

TXMD Hedge Fund Activity: Q3 2025 in Review

46 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2025, worth a combined $3.54M — down 6.2% from $3.78M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TXMD positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 11 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $38.4K. The largest seller was UBS Group, cutting an estimated $4.64K.

  • 46 institutional investors held TherapeuticsMD (TXMD) as of Q3 2025, up from 42 in Q2 2025.
  • Funds reported $3.54M of TherapeuticsMD stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 7 funds opened new TherapeuticsMD positions in Q3 2025 and 3 closed out, a net change of +4 holders.
  • The largest TherapeuticsMD buyer in Q3 2025 was Citadel Advisors, an estimated $38.4K added.
  • The largest TherapeuticsMD seller in Q3 2025 was UBS Group, an estimated $4.64K sold.

Based on aggregated 13F filings for Q3 2025.